

## Herceptin - (21mg/mL; Vial, Intravenous)

|                              |                                                                                                                                                                                                                                                                               |                             |                     |
|------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|---------------------|
| <b>Generic Name</b>          | Trastuzumab                                                                                                                                                                                                                                                                   | <b>Innovator</b>            | Genentech, Inc.     |
| <b>Dosage</b>                | 21mg/mL; Vial, Intravenous                                                                                                                                                                                                                                                    | <b>Branded US Sales</b>     | More Than \$1000 mn |
| <b>Probable FTF</b>          | None                                                                                                                                                                                                                                                                          | <b>Known Para IV Filers</b> | More Than 5         |
| <b>Other ANDA developers</b> | More Than 5                                                                                                                                                                                                                                                                   | <b>Tentative Approvals</b>  | None                |
| <b>Final Approvals</b>       | More Than 5                                                                                                                                                                                                                                                                   | <b>Generic Launches</b>     | More Than 5         |
| <b>Indication</b>            | Herceptin is indicated, in combination with cisplatin and capecitabine or 5-fluorouracil, for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease. |                             |                     |
| <b>Complexities</b>          | Yes                                                                                                                                                                                                                                                                           |                             |                     |

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.